These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 10433577)
21. Immunogenicity and safety of a new Vero cell rabies vaccine produced using serum-free medium. Costa WA; Cunha RS; Bolzan VL; Silva Ade C; Caporale GM; Chaves LB; Oselka GW; Junqueira DA; Panacho MR; Dias RA; Takaoka NY Vaccine; 2007 Nov; 25(48):8140-5. PubMed ID: 18029066 [TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and booster efficacy of pre-exposure rabies vaccination. Strady C; Andreoletti L; Baumard S; Servettaz A; Jaussaud R; Strady A Trans R Soc Trop Med Hyg; 2009 Nov; 103(11):1159-64. PubMed ID: 19359026 [TBL] [Abstract][Full Text] [Related]
23. An effective economical intradermal regimen of human diploid cell rabies vaccination for post-exposure treatment. Ubol S; Phanuphak P Clin Exp Immunol; 1986 Mar; 63(3):491-7. PubMed ID: 3708902 [TBL] [Abstract][Full Text] [Related]
24. Serologic response to rabies pre-exposure vaccination in persons with potential occupational exposure in Singapore. Lim PL; Barkham TM Int J Infect Dis; 2010 Jun; 14(6):e511-3. PubMed ID: 20018545 [TBL] [Abstract][Full Text] [Related]
25. Antibody persistence, 32 years after post-exposure prophylaxis with human diploid cell rabies vaccine (HDCV). Fayaz A; Simani S; Janani A; Farahtaj F; Biglari P; Howeizi N; Eslami N Vaccine; 2011 May; 29(21):3742-5. PubMed ID: 21458608 [TBL] [Abstract][Full Text] [Related]
26. Preventing rabies with the Verorab vaccine: 1985-2005 Twenty years of clinical experience. Toovey S Travel Med Infect Dis; 2007 Nov; 5(6):327-48. PubMed ID: 17983973 [TBL] [Abstract][Full Text] [Related]
27. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen. Ambrozaitis A; Laiskonis A; Balciuniene L; Banzhoff A; Malerczyk C Vaccine; 2006 May; 24(19):4116-21. PubMed ID: 16545510 [TBL] [Abstract][Full Text] [Related]
28. Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine. Tantawichien T; Benjavongkulchai M; Limsuwan K; Khawplod P; Kaewchompoo W; Chomchey P; Sitprija V Clin Infect Dis; 1999 May; 28(5):1100-3. PubMed ID: 10452642 [TBL] [Abstract][Full Text] [Related]
29. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Vien NC; Feroldi E; Lang J Trans R Soc Trop Med Hyg; 2008 Mar; 102(3):294-6. PubMed ID: 18191971 [TBL] [Abstract][Full Text] [Related]
30. Intradermal pre-exposure rabies immunisation in New Zealand. Shaw MM; Leggat PA; Williams ML Travel Med Infect Dis; 2006 Jan; 4(1):29-33. PubMed ID: 16887722 [TBL] [Abstract][Full Text] [Related]
31. Immunogenicity and safety of WHO-approved TRC-ID regimen with a chromatographically purified Vero cell rabies vaccine with or without rabies immunoglobulin in children. Angsuwatcharakon P; Khomvilai S; Limsuwun K; Ratananpinit N; Khamchat A; Sanitnai T; Tantawichien T Expert Rev Vaccines; 2018 Feb; 17(2):185-188. PubMed ID: 29285961 [TBL] [Abstract][Full Text] [Related]
32. Persistence of antibodies in children after intradermal or intramuscular administration of preexposure primary and booster immunizations with purified Vero cell rabies vaccine. Sabchareon A; Chantavanich P; Pasuralertsakul S; Pojjaroen-Anant C; Prarinyanupharb V; Attanath P; Singhasivanon V; Buppodom W; Lang J Pediatr Infect Dis J; 1998 Nov; 17(11):1001-7. PubMed ID: 9849982 [TBL] [Abstract][Full Text] [Related]
33. Studies on clinical trials and immune effect of a new purified rabies vaccine prepared from Vero cells. Dong G; Zheng H; Liu Z Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Mar; 14(1):19-23. PubMed ID: 11503018 [TBL] [Abstract][Full Text] [Related]
34. Revision of the Thai Red Cross intradermal rabies post-exposure regimen by eliminating the 90-day booster injection. Khawplod P; Wilde H; Sirikwin S; Benjawongkulchai M; Limusanno S; Jaijaroensab W; Chiraguna N; Supich C; Wangroongsarb Y; Sitprija V Vaccine; 2006 Apr; 24(16):3084-6. PubMed ID: 16494972 [TBL] [Abstract][Full Text] [Related]
35. Intradermal use of human diploid cell vaccine for preexposure rabies immunizations. Dreesen DW; Sumner JW; Brown J; Kemp DT J Am Vet Med Assoc; 1982 Dec; 181(12):1519-23. PubMed ID: 7161170 [TBL] [Abstract][Full Text] [Related]
36. Antibody response after a two-year intradermal booster of rabies human diploid cell vaccine. Horman JT; Rullán JV; Myers RA; Bond JO; Israel E; Joseph JM J Am Vet Med Assoc; 1987 Jul; 191(2):185-7. PubMed ID: 3610792 [TBL] [Abstract][Full Text] [Related]
37. Pre-exposure purified vero cell rabies vaccine and concomitant routine childhood vaccinations: 5-year post-vaccination follow-up study of an infant cohort in Vietnam. Lang J; Feroldi E; Vien NC J Trop Pediatr; 2009 Feb; 55(1):26-31. PubMed ID: 18048461 [TBL] [Abstract][Full Text] [Related]
38. A three-year clinical study on immunogenicity, safety, and booster response of purified chick embryo cell rabies vaccine administered intramuscularly or intradermally to 12- to 18-month-old Thai children, concomitantly with Japanese encephalitis vaccine. Pengsaa K; Limkittikul K; Sabchareon A; Ariyasriwatana C; Chanthavanich P; Attanath P; Malerczyk C Pediatr Infect Dis J; 2009 Apr; 28(4):335-7. PubMed ID: 19333080 [TBL] [Abstract][Full Text] [Related]
39. Rabies antibody seroprotection rates among travelers in Nepal: "rabies seroprotection in travelers". Ranney M; Partridge R; Jay GD; Rozzoli DE; Pandey P J Travel Med; 2006; 13(6):329-33. PubMed ID: 17107424 [TBL] [Abstract][Full Text] [Related]